Silvio E. Inzucchi
Brigham and Women's Hospital
2 papers in the Anchorcite directory, published between 2015 and 2019, cited 20,125 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 2 papers
- Heart Failure Treatment and Management · 2 papers
- Diabetes, Cardiovascular Risks, and Lipoproteins · 1 paper
- Cardiovascular Function and Risk Factors · 1 paper
Frequent co-authors
- Bernard Zinman · 1 paper
- Christoph Wanner · 1 paper
- John M. Lachin · 1 paper
- DAVID H. FITCHETT · 1 paper
- Erich Bluhmki · 1 paper
- Stefan Hantel · 1 paper
- Michaela Mattheus · 1 paper
- Theresa Devins · 1 paper
Papers
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine · 2015 · 12,596 citations
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to…
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…
Metadata from OpenAlex (CC0).